Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Hematology
Published in: Annals of Hematology 10/2014

01-10-2014 | Letter to the Editor

Pneumatosis intestinalis and imatinib mesylate

Authors: Ciara O’Rafferty, Fiona McElligott, Lorna Storey, Aengus O’Marcaigh, Owen Smith

Published in: Annals of Hematology | Issue 10/2014

Login to get access

Excerpt

Dear Editor, …
Literature
1.
Coriat R, Ropert S, Mir O et al (2011) Pneumatosis intestinalis associated with treatment of cancer patients with the vascular growth factor receptor tyrosine kinase inhibitors sorafenib and sunitinib. Invest New Drugs 29:1090–1093PubMedCrossRef
2.
Shinagare AB, Howard SA, Krajewski KM, Zukotynski KA, Jagannathan JP, Ramaiya NH (2012) Pneumatosis intestinalis and bowel perforation associated with molecular targeted therapy: an emerging problem and the role of radiologists in its management. AJR Am J Roentgenol 199:1259–1265PubMedCrossRef
3.
Viswanathan C, Bhosale P, Ganeshan DM, Truong MT, Silverman P, Balachandran A (2012) Imaging of complications of oncological therapy in the gastrointestinal system. Cancer Imaging 12:163–172PubMedCentralPubMedCrossRef
4.
Asmis TR, Chung KY, Teitcher JB, Kelsen DP, Shah MA (2008) Pneumatosis intestinalis: a variant of bevacizumab related perforation possibly associated with chemotherapy related GI toxicity. Invest New Drugs 26:95–96PubMedCrossRef
5.
Kashima T, Ohno Y, Tachibana M (2012) Pneumatosis intestinalis and hepatic portal venous gas in a patient receiving sorafenib. Int J Urol 19:1041–1042PubMedCrossRef
6.
Choi YA, Sim EH, Lee KE et al (2013) A case of pneumatosis intestinalis associated with sunitinib treatment for renal cell carcinoma. Korean J Gastroenterol 61:347–350PubMedCrossRef
7.
Jarkowski A 3rd, Hare R, Francescutti V, Wilkinson N, Khushalani N (2011) Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor. Anticancer Res 31:3429–3432PubMed
8.
Vijayakanthan N, Dhamanaskar K, Stewart L et al (2012) A review of pneumatosis intestinalis in the setting of systemic cancer treatments, including tyrosine kinase inhibitors. Can Assoc Radiol J 63:312–317PubMedCrossRef
Metadata
Title
Pneumatosis intestinalis and imatinib mesylate
Authors
Ciara O’Rafferty
Fiona McElligott
Lorna Storey
Aengus O’Marcaigh
Owen Smith
Publication date
01-10-2014
Publisher
Springer Berlin Heidelberg
Published in
Annals of Hematology / Issue 10/2014
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-014-2051-y

Other articles of this Issue 10/2014

Annals of Hematology 10/2014 Go to the issue

Letter to the Editor

Recombinant human interleukin-10 in patients with chronic myelomonocytic leukemia

Original Article

Prevalence of anemia among elderly inpatients and its association with multidimensional loss of function

Original Article

Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1

Letter to the Editor

The successful management of dabigatran-associated critical end-organ bleeding with recombinant factor VIIa

Original Article

A novel scoring system to predict the incidence of invasive fungal disease in salvage chemotherapies for malignant lymphoma

Letter to the Editor

Paraneoplastic disseminated intravascular coagulation caused by splenic littoral cell angioma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits